E.E. Dumbrava - Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 19 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1075TiP A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors

E.E. Dumbrava,E. Calvo, E. Garralda, M.H. Ryu,D-Y. Oh,L-Y. Bai,W. Chung,K.I. Rojas Laimito,O. Yildirim, S. Masciari, K. Kang, B. Buday,

Annals of Oncology (2023): S647-S647

引用0浏览0引用

B.T. Li,K-W. Lee, M. Pegram, M.R. Sharma, J. Lee, A.I. Spira,Y-K. Kang, K.N. Moore, D. Rasco, G.J. Hanna, B.A. Weinberg, T. Yu,

Annals of Oncology (2023): S462-S463

引用0浏览0引用

701P NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)

T.A. Yap, S.A. Piha-Paul, D. Karp,E.E. Dumbrava, D.S. Hong, S. Fu, V. Subbiah, A.M. Tsimberidou, J. Rodon, J. Rhudy, C. Valladolid, Y. Yuan,

Annals of Oncology (2023): S487-S488

引用0浏览0引用

DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations

N. Ngoi, P.G. Pilie, S.A. Piha-Paul,E.E. Dumbrava, S. Fu, D.S. Hong, D.D. Karp, A. Naing, S. Pant,J. Rodon Ahnert, V. Subbiah,A.M. Tsimberidou,

European Journal of Cancer（2022）

引用0浏览0引用

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors

H. Park,G.I. Shapiro, X. Gao,A. Mahipal,J. Starr,M. Furqan,P. Singh, A. Ahrorov,L. Gandhi,A. Ghosh, D. Hickman, P.D. Gallacher,

ESMO Open（2022）

引用10浏览0WOS引用

Results from phase I dose escalation of IMC-F106C, the first PRAME X CD3 ImmTAC bispecific protein in solid tumors

O. Hamid,T. Sato, D. Davar,M. K. Callahan,F. Thistlethwaite, R. Aljumaily,M. L. Johnson,H-T. Arkenau,E. E. Ileana Dumbrava,B. Izar,H. A. Chen, S. Marshall,

Annals of Oncologyno. 7 (2022): S875-S875

引用0浏览0引用

778TiP A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors

B.L. Schlechter,E.E. Ileana Dumbrava,D. Olson,S. Saibil,B. Pieke,R. Bouvier,K. Moss, N. Turnus,A. Bader,D. Adib

Annals of Oncology (2022): S896-S896

引用0浏览0引用

485P Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials

N.Y.L. Ngoi, H. Lin,E.E. Ileana Dumbrava, S. Fu, D. Karp, A. Naing, S. Pant, J. Rodon, S. Piha-Paul, V. Subbiah, A.M. Tsimberidou, E. Campbell,

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 ..

T.A. Yap, N. Ngoi,E.E. Dumbrava, D.D. Karp,J. Rodon Ahnert, S. Fu, D.S. Hong, A. Naing, S. Pant, S.A. Piha-Paul, V. Subbiah,A.M. Tsimberidou,

European Journal of Cancer（2022）

引用0浏览0引用

46P Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors

D. Oh, J. Henry, J.C. Baranda,E.E. Dumbrava,E. Cohen, J.D. Eskew, R. Belani, J. McCaigue, H. Namini, C. Martin, A. Murphy, E. Ostertag,

Immuno-Oncology and Technology (2022): 100151

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn